---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-005010"
form_type: "8-K"
ticker: "BBNX"
cik: "0001674632"
company_name: "Beta Bionics, Inc."
filed_at: "2026-07-29T20:04:17+00:00"
generated_at: "2026-07-29T20:05:10.181589+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Beta Bionics Q2 net sales up 38% to $32M; gross margin expands 524 bps to 59%

## Summary
- Net sales $32.0M, up 38% YoY; PBP channel sales surged 153% to $11.6M.
- Gross margin 59.0%, up 524 bps from 53.8% in Q2 2025.
- Net loss $23.4M (negative 73% of sales) vs $16.9M (negative 73%) YoY.
- Adjusted EBITDA negative $17.7M (negative 55% of sales) vs negative $14.5M (negative 63%).
- Cash and investments $225.2M as of June 30, 2026; full year 2026 guidance updated (specifics not provided in excerpt).

## SEC filing metadata
- accession: 0001171843-26-005010
- form_type: 8-K
- ticker: BBNX
- cik: 0001674632
- company_name: Beta Bionics, Inc.
- filed_at: 2026-07-29T20:04:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674632/000117184326005010/0001171843-26-005010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674632/000117184326005010/f8k_072826.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-005010
- JSON: https://secwatch.observer/filing/0001171843-26-005010.json
- Plain text: https://secwatch.observer/filing/0001171843-26-005010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.